Bone Historical Income Statement
| BBLGW Stock | USD 27.80 0.00 0.00% |
Historical analysis of Bone Biologics income statement accounts such as Ebitda of 503.6 K, Total Operating Expenses of 4.7 M or Gross Profit of 0.0 can show how well Bone Biologics Corp performed in making a profits. Evaluating Bone Biologics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bone Biologics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bone Biologics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bone Biologics Corp is a good buy for the upcoming year.
Bone |
About Bone Income Statement Analysis
Bone Biologics Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bone Biologics shareholders. The income statement also shows Bone investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bone Biologics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bone Biologics Corp. It is also known as Bone Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Bone Biologics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At this time, Bone Biologics' Other Operating Expenses is fairly stable compared to the past year. EBITDA is likely to climb to about 503.6 K in 2024, despite the fact that EBIT is likely to grow to (8.5 M).
| 2022 | 2023 | 2024 (projected) | Tax Provision | 3.2K | 3.7K | 2.1K | Interest Expense | 2.2M | 2.0M | 1.5M |
Bone Biologics income statement Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 2.4M | 825.0K | 1.1M | 3.7M | 9.4M | 9.9M | |
| Operating Income | (2.4M) | (825.0K) | (1.1M) | (3.7M) | (9.4M) | (9.0M) | |
| Ebit | (2.4M) | (825.0K) | (1.1M) | (4.6M) | (8.9M) | (8.5M) | |
| Ebitda | (2.4M) | (825.0K) | (1.1M) | (4.4M) | 479.6K | 503.6K | |
| Total Operating Expenses | 2.4M | 825.0K | 1.1M | 3.7M | 9.4M | 4.7M | |
| Income Before Tax | (3.4M) | (1.8M) | (1.6M) | (1.5M) | (8.9M) | (8.5M) | |
| Net Income | (3.4M) | (1.8M) | (1.6M) | 695.9K | (8.9M) | (8.5M) | |
| Depreciation And Amortization | 50.0 | 0.05 | 1.1K | 228.5K | 9.4M | 9.9M | |
| Selling General Administrative | 1.4M | 484.3K | 1.0M | 2.1M | 2.5M | 2.0M | |
| Research Development | 1.1M | 340.7K | 82.0K | 1.6M | 6.9M | 7.3M | |
| Total Other Income Expense Net | (975.8K) | (998.1K) | (507.6K) | 2.2M | 479.6K | 503.6K | |
| Interest Expense | 975.8K | 998.1K | 805.1K | 2.2M | 2.0M | 1.5M | |
| Net Interest Income | (975.8K) | (998.1K) | (805.1K) | (731.7K) | (730.2K) | (766.7K) | |
| Net Income From Continuing Ops | (3.4M) | (1.8M) | (1.6M) | (1.5M) | (6.5M) | (6.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.